Neonatal platelet physiology and implications for transfusion.

Area of Science:

• Hematology
• Neonatal Physiology
• Developmental Biology

Background:

• Neonatal hemostasis differs significantly from adult hemostasis, a phenomenon termed "developmental hemostasis."
• While platelet counts are similar, neonatal platelets exhibit functional hyporeactivity to various agonists compared to adult platelets.
• This hyporeactivity is more pronounced in preterm neonates and linked to altered surface receptor expression and signaling pathways.

Purpose of the Study:

• To delineate the developmental differences in platelet function and primary hemostasis between neonates and adults.
• To analyze the implications of these unique hemostatic characteristics on clinical transfusion practices.
• To critically evaluate the efficacy and safety of prophylactic platelet transfusions in preterm infants.

Main Methods:

• Comparative analysis of platelet function and primary hemostasis markers in neonatal and adult blood samples.
• Review of existing literature on neonatal hemostasis, platelet reactivity, and clinical outcomes.
• Examination of factors influencing platelet-vessel wall interactions in neonates, including von Willebrand factor (vWF) and hematocrit levels.

Main Results:

• Neonatal platelets show reduced reactivity to agonists, yet healthy term infants have shorter bleeding and closure times than adults.
• Enhanced primary hemostasis in neonates is attributed to high von Willebrand factor (vWF) levels, ultralong vWF multimers, high hematocrit, and increased red cell volume.
• Prophylactic platelet transfusions in preterm neonates have not shown a decrease in bleeding and are associated with increased morbidity and mortality.

Conclusions:

• Neonatal platelet hyporeactivity is an adaptive feature of a unique, balanced primary hemostatic system, not a deficiency.
• Current arbitrary limits for platelet transfusions in neonates require re-evaluation based on developmental hemostasis principles.
• Evidence suggests reconsidering prophylactic platelet transfusions in preterm infants due to potential harm and lack of demonstrated benefit.